NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Meirluc,

I don't agree with your analysis.
You said:

Another thing I did not mention before is that it is very likely that the overwhelming majority of the crossover group was composed of methylated GBM patients.

Here are the NYAS DATA:

64 rGBM DCVax-L patients (crossover group)
- 44% methylated (28 rGBM DCVax-L patients)
- 52% unmethylated (33 rGBM DCVax-L patients)
- 5% missing (3 rGBM DCVax-L patients)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168826841

Here are some facts about the 35 non-crossover patients (NYAS data):
at least (probably more) 13 of 35 have no evidence of disease progression 12 months after randomization and 8 of these patients have no evidence of disease progression 24 months after randomization.
Why do you think the mOS of the 35 patients was shorter than 12 months?